# 



|CONTENTS||PAGE|
|---|---|---|
|Legal and administrative|details||
|Report ofthe Trustees|||
|Independent<br>Examiner's|Report||
|Statement offinancial<br>activities|||
|Balance sheet|||
|Notes to the financial statements||S-e|





## 

## 

## 

|Jeremy|Chataway|- Chairman|
|---|---|---|
|Omar Malik|||
|Richard|Nicholas||
|10L18Laboratory||Block|
|Charing|Cross Campus||
|Imperial|College|London|
|Fulham|Palace Road||
|Hammersmith|||
|London|||
|W6 8RF|||



|Charity Number|Charity Number|1113598|
|---|---|---|
|Accountants|and|Haines Watts|
|Independent|Examiners|Aissela|
|||46 High Street|
|||Esher|
|||Surrey|
|||KT10 9QY|





## 



## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

|||Note||Unrestricted|Restricted|Year to|Year to|
|---|---|---|---|---|---|---|---|
|||||Funds|Funds|2022|2021|
|||||6|6|K|6|
|Income and endowments|from:|||||||
|Donations<br>and legacies<br>Charitable<br>activities||||57,770||57,770|3,263|
|Total income||||57,770||57,770|3,263|
|Expenditure<br>on:||||||||
|Grants and Donafons Paid<br>Charitable<br>activities||||23,966<br>2,173||23,966<br>2,173|41,162<br>(420)|
|Total expenditure||||26 139||26,139|40,742|
|Net (expenditure)/income|and net|movement|in funds|31,631||31,631|~37479,|
|Reconciliation<br>offunds:||||||||
|Total funds<br>brought forward||||171,615|10,200|181,815|219,294|
|Total funds carried forward||||203,246|10,200|213,446|181,815|





## 




## 

## 

## 

## 

## 

## 

## 


## 



## 

## 


## 

## 

## 

|Creditors|||||||
|---|---|---|---|---|---|---|
||||||Yearto|Year to|
||||||2022f|2021f|
|Accrued grants payable|||||||
|Accrued support costs|||||1,200|1,200|
||||||1,200|1,200|
|Unrestricted|funds||||||
|Year ended|31 March 2022|Balance at<br>01/04/2021f|Incomef|Expendituref|Transfersf|Balance at<br>31/03/2022f|
|General funds||171,615|57,770|(26,139)||203,246|
|||171,615|57,770|(26,139)||203,246|
|Year ended|31 March 2021|Balance at<br>01/04/2020f|Incomef|Expenditure|Transfersf|Balance at<br>31/03/2021f|
|General funds||209,094<br>209,094|3,263<br>3.263|(40,742)<br> ~40742,||171,615<br>171,615|





## 

## 

|Restricted funds|Restricted funds||||||||
|---|---|---|---|---|---|---|---|---|
|Year ended 31March 2022||Balance at<br>01/04/2021<br>2|Income<br>f|||Expenditure|Transfers<br>8|Balance at<br>31/03/2022|
|Genzyme|Therapsut|10,200||||||10,200|
|||10,200||||||10,200|
|Year ended 31March 2021||Balance at<br>01/04/2020<br>8|Income<br>8|||Expenditure<br>2|Transfers|Balance at<br>31/03/2021<br>K|
|Genzyms|Therapeut|10,200||||||10,200|
|||10,200||||||10,200|
|Name of|fund|Descri<br>ion nature and||u|uses|ofthe fund|||
|Genzyme|Therapeut|Funds held for the|purpose|of|making|a grant for the|purchase ofan|infusion<br>pump.|



|enzyme<br>Therapeut<br>Funds held f<br>Analysis ofnet assets between funds|enzyme<br>Therapeut<br>Funds held f<br>Analysis ofnet assets between funds|or the purpose ofmaking a grant for the|purchase ofan infus|ion<br>pump.|
|---|---|---|---|---|
|Year ended 31March 2022||Unrestricted<br>Funds|Restricted<br>Funds<br>8|Totalf|
|Current <br>Current|assets<br>liabilities|204,446<br>(1,200)|10,200|214,646<br>(1,200)|
|||203,246|10,200|213,446|
|Year ended 31 March 2021||Unrestricted<br>Funds<br>8|Restricted<br>Fundsf|Total|
|Current <br>Current|assets<br>liabilities|172,815<br>(1,200)|10,200|183,015<br>(1,200)|
|||171,615|10,200|181,815|